ROMIDEPSIN

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H36N4O6S2
Molecular Weight	540.696
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure of ROMIDEPSIN

Structure Search

SMILES

[H][C@]12CC(=O)N[C@H](C(C)C)C(=O)N[C@]([H])(CSSCC\C=C\1)C(=O)N\C(=C/C)C(=O)N[C@@H](C(C)C)C(=O)O2

InChI

InChIKey=OHRURASPPZQGQM-GCCNXGTGSA-N

InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C24H36N4O6S2
Molecular Weight	540.696
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://pubmed.ncbi.nlm.nih.gov/26331334

FR-135313 (also known as Romidepsin reduced) was studied as a selective inhibitor of the human histone deacetylase 1 (HDAC1).

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
Histone deacetylase 1 51 Target ID: Q13547 Gene ID: 3065.0 Gene Symbol: HDAC1 Target Organism: Homo sapiens (Human) Sources: https://pubmed.ncbi.nlm.nih.gov/26331334	Inhibitor 8297		0.12 nM [IC50]

Sample Use Guides

In Vitro Use Guide

Inhibition of recombinant human HDAC1 after 60 mins by fluorescence assay with IC50 = 0.00012 uM

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:47:36 GMT 2023` Edited by `admin` on `Fri Dec 15 15:47:36 GMT 2023`
Record UNII	CX3T89XQBK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ROMIDEPSIN

Official Name

English

FK-228

Code

English

ROMIDEPSIN [MART.]

Common Name

English

CHROMADAX

Brand Name

English

(1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

Systematic Name

English

ROMIDEPSIN [JAN]

Common Name

English

CYCLO((2Z)-2-AMINO-2-BUTENOYL-L-VALYL-(3S,4E)-3-HYDROXY-7-MERCAPTO-4-HEPTENOYL-D-VALYL-D-CYSTEINYL), CYCLIC (3->5)-DISULFIDE

Common Name

English

Depsipeptide [WHO-DD]

Common Name

English

DEPSIPEPTIDE

Common Name

English

FK228

Code

English

ROMIDEPSIN [MI]

Common Name

English

Romidepsin [WHO-DD]

Common Name

English

ROMIDEPSIN [USAN]

Common Name

English

romidepsin [INN]

Common Name

English

ROMIDEPSIN [ORANGE BOOK]

Common Name

English

ISTODAX

Brand Name

English

NSC-630176

Code

English

ROMIDEPSIN [VANDF]

Common Name

English

FR-901228

Code

English

FR901228

Code

English

CYCLO((2Z)-2-AMINO-2-BUTENOYL-L-VALYL-(3S,4E)-3-HYDROXY-7-MERCAPTO-4-HEPTENOYL-D-VALYL-D-CYSTEINYL), CYCLIC (3->5)-DISULPHIDE

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

193404

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

EMA ASSESSMENT REPORTS

ISTODAX (REFUSED: LYMPHOMA, NON-HODGKIN)

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

NCI_THESAURUS

C1946

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

WHO-ATC

L01XX39

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

LIVERTOX

NBK548380

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

NDF-RT

N0000175588

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

WHO-VATC

QL01XX39

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

NCI_THESAURUS

C1976

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

Code System Code Type Description

INN

8656

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

MERCK INDEX

m9652

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

Merck Index

NSC

630176

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

EVMPD

SUB26362

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

USAN

SS-77

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

DAILYMED

CX3T89XQBK

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

EU-Orphan Drug

EU/3/05/279(POSITIVE)

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

On 27 May 2005, orphan designation (EU/3/05/279) was granted by the European Commission to The Matthews Consultancy Ltd, United Kingdom, for (E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone (depsipeptide) for the treatment of cutaneous T cell lymphoma. The sponsorship was transferred to Gloucester Pharmaceuticals Limited, United Kingdom, in October 2008 and to Celgene Europe Limited, United Kingdom, in September 2010.

CHEBI

61080

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

MESH

C087123

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

EU-Orphan Drug

EU/3/05/328(POSITIVE)

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

On 28 October 2005, orphan designation (EU/3/05/328) was granted by the European Commission to The Matthews Consultancy Ltd, United Kingdom, for (E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone (also known as “depsipeptide”) for the for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated). The sponsorship was transferred to Gloucester Pharmaceuticals Limited, United Kingdom, in October 2008 and to Celgene Europe Limited, United Kingdom, in September 2010.

ChEMBL

CHEMBL1213490

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

IUPHAR

7006

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

SMS_ID

100000091284

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

FDA UNII

CX3T89XQBK

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

RXCUI

877510

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

RxNorm

EPA CompTox

DTXSID8048579

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

WIKIPEDIA

ROMIDEPSIN

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

NCI_THESAURUS

C1544

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

PUBCHEM

5352062

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

DRUG BANK

DB06176

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

DRUG CENTRAL

4119

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

CAS

128517-07-7

Created by admin on Fri Dec 15 15:47:36 GMT 2023 , Edited by admin on Fri Dec 15 15:47:36 GMT 2023

PRIMARY

Related Record Type Details


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					859A956UY8

HUMAN IMMUNODEFICIENCY VIRUS TYPE 1

TARGET ORGANISM->INHIBITOR

Amount:


					RV2QAE6UDF

HISTONE DEACETYLASE 2

TARGET -> INHIBITOR

Comments:

Potent HDAC2 inhibitor in a cell-free assay.

Interaction Type:

INHIBITOR

Qualification:

IC50

Amount:


					O037NFL7YQ

HISTONE DEACETYLASE 1

TARGET -> INHIBITOR

Comments:

Potent HDAC1 inhibitor in a cell-free assay.

Interaction Type:

INHIBITOR

Qualification:

IC50

Amount:

Related Record Type Details


					4MQ5UQAIB8

FR-135313

METABOLITE ACTIVE -> PRODRUG

Related Record Type Details


					4MQ5UQAIB8

FR-135313

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Volume of Distribution	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC